-
New Drug Combo to Battle Thyroid Cancer
Share this:
There's promising news in the battle against anaplastic thyroid cancer (ATC), a rare but aggressive and devastating form of thyroid cancer that typically strikes men and women in their 60s and 70s. The median survival is about 5 months from time of diagnosis.
A Mayo Clinic-led study, published in the journal Science Translational Medicine , reveals the combination of pazopanib and paclitaxel can slow the cancer growth.
Click here for news release
Sound bites with lead researcher, Keith Bible, M.D.,Ph.D., are available in the downloads above
Expert title for broadcast cg: Dr. Keith Bible, Mayo Clinic Oncologist
Share this:
Related articles
The types of cancer that occur in children often are different from those in adults. Childhood cancers usually are not linked to lifestyle or environmental ...
September is Childhood Cancer Awareness Month. The most common type of childhood cancer is acute lymphocytic leukemia (ALL), a blood and bone marrow cancer that creates immature white ...
DEAR MAYO CLINIC: I recently heard about a type of skin cancer called Merkel cell carcinoma. I'm not familiar with this condition. Can you explain ...